4:45 PM - 5:00 PM (PDT), Wednesday, June 15, 2022
OncoOne is a Vienna-based biotech dedicated to the development of novel therapeutics for patients with solid tumors and autoimmune diseases. OncoOne's founders identified the disease-related isoform of one of the most important drivers of innate and adaptive immunity, the macrophage migration inhibitory factor (MIF).
OncoOne has overcome the limitations of targeting MIF by harnessing the high tumor-specificity of the disease-related and druggable isoform of MIF which their founders discovered and named oxidized MIF (oxMIF). OncoOne is r advancing their lead asset ON203, an optimized oxMIF mAb, to clinic in early 2023.
ON104 is an oxMIF mAb specifically formulated for patients with autoimmune disorders and inflammatory conditions. ON104 has great potential to improve upon the current standards of care in rheumatoid arthritis, ulcerative colitis, Crohn’s disease, refractory asthma, and other autoimmune disorders.
OncoOne initiated investor discussions this year to secure Series B fund
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
ON203 anti-oxMIF mAb
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided